Dr. Vorobiof on Financial Toxicity in Oncology

Video

Daniel A. Vorobiof, MD, discusses financial toxicity in oncology.

Daniel A. Vorobiof, MD, chief medical director of Belong.Life, discusses financial toxicity in oncology.

Financial toxicity is an ongoing problem in the oncology space that has not been properly addressed to date, Vorobiof says.

In the United States, cancer is among the most expensive diseases to treat, along with heart disease, Vorobiof says. Moreover, financial toxicity is a global problem and cancer-related treatment expenses are continuing to rise.

Although financial toxicity may affect all patients differently, some health care professionals have been detached from the widespread burden financial toxicity can place on a patient with cancer, concludes Vorobiof.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD
Sundar Jagannath, MBBS
Nikhil Gopal, MD, assistant professor, urology, College of Medicine, Memphis Department of Urology, The University of Tennessee Health Science Center